Adicet Bio (ACET) investor relations material

Key program updates and clinical progress

• Gamma delta 1 T cell platform offers off-the-shelf dosing, favorable safety, and broad outpatient accessibility.

• Prula-cel (ADI-001) targets CD20 and is being evaluated in multiple autoimmune indications, with primary focus on lupus nephritis (LN), SLE, and systemic sclerosis.

• Upcoming mid-year data update will include over 20 patients with at least six months of follow-up, focusing on efficacy and durability in LN and SLE.

• Systemic sclerosis cohort is small but may provide pivotal study insights; endpoints include lung function stabilization and skin score improvements.

• RA cohort is designed to compare lymphodepletion regimens, with enrollment ongoing and early data pending.

Efficacy, safety, and competitive landscape

• Efficacy of prula-cel appears comparable to autologous CAR T therapies, with potential for broader access due to off-the-shelf nature.

• Safety profile shows lower rates and severity of CRS and ICANS compared to alpha beta T cells, enabling outpatient dosing.

• Data suggest complete CD19 B cell depletion despite CD20 targeting, aligning efficacy with CD19-focused therapies.

• T cell engagers and bispecifics may require chronic dosing and carry long-term immunosuppression risks, while prula-cel aims for one-time durable benefit.

• Indication expansion is under consideration, with MS and other autoimmune diseases as future possibilities.

Pipeline and financial outlook

• ADI-212, a PSMA-targeted gamma delta T cell therapy for solid tumors, incorporates MED12 knockout and membrane-bound IL-12 for enhanced efficacy; IND filing expected in Q3 with phase I enrollment in Q4.

• In vivo CAR T program remains undisclosed but is positioned as a future catalyst.

• Cash runway extends into the second half of next year, supporting ongoing and upcoming clinical milestones.